Figure 1. Overall survival curves for 22 patients with non-small cell lung cancer (NSCLC) from the start of re-challenge chemotherapy with gemcitabine plus carboplatin (rGC).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.